Abstract 4861: Oral immune checkpoint antagonists targeting PD-L1VISTA or PD-L1Tim3 for cancer therapy

Recent successes in achieving highly durable clinical responses with antibodies to immune checkpoint receptors such as CTLA4 and PD1 have transformed the outlook for cancer therapy. While these antibody-based therapies show impressive clinical activity, they suffer from the shortcomings including th...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2016-07, Vol.76 (14_Supplement), p.4861-4861
Main Authors: Sasikumar, Pottayil, Sudarshan, N S, Gowda, Nagaraj, Samiulla, D S, Ramachandra, Raghuveer, Chandrasekhar, T, Adurthi, Sreenivas, Mani, Jiju, Nair, Rashmi, Singh, Sharad, Dhudashia, Amit, Gowda, Nagesh, Ramachandra, Murali
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent successes in achieving highly durable clinical responses with antibodies to immune checkpoint receptors such as CTLA4 and PD1 have transformed the outlook for cancer therapy. While these antibody-based therapies show impressive clinical activity, they suffer from the shortcomings including the need to administer by intravenous injection, failure to show response in majority of patients and immune-related adverse events (irAEs) due to the breaking of immune self-tolerance. Sustained target inhibition as a result of a long half-life (>15-20 days) and >70 target occupancy for months may be factors contributing to irAEs observed.
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2016-4861